QT VASCULAR LTD.
(Company Registration No.: 201305911K)
(Incorporated in Singapore)

QT VASCULAR LTD. REDUCES TRADE DEBT BY S$691,000 VIA SETTLEMENT WITH SHARES

---

1. INTRODUCTION

The Board of Directors (the "**Board**") of QT Vascular Ltd. (the "**Company**"), and together with its subsidiaries (the "**Group**") wishes to announce that it has on 21 July 2017, issued 22,290,322 new ordinary shares in the capital of the Company (the "**New Shares**"), to an independent third party (the "**Creditor**") for settlement of trade payables amounting to S$691,000 ("**Trade Payables**") ("**Shares Settlement**"), as further elaborated herein ("**Proposed Issue**").

The Shares Settlement is pursuant to (i) trade payables amounting to S$691,000; and (ii) the repayment agreement dated 9 June 2017 between the Creditor and the Company in relation to the repayment of the trade payables ("**Repayment Agreement**").

Pursuant to the Repayment Agreement, the Company has settled the S$691,000 owing to the Creditor by way of the allotment and issuance of 22,290,322 New Shares at the issue price equivalent to the daily volume weighted average price of the Shares based on trades done on SGX-ST on the date of the Repayment Agreement, being S$0.031 per New Share. Upon satisfaction of the aforementioned, the Creditor shall cease to have any rights or claims whatsoever against the Company and its subsidiaries ("**Group**") under or in connection with, the Trade Payables.

The Creditor do not fall within the categories set out in Rule 812 (1) of the Listing Manual Section B: Rules of Catalist of the SGX-ST.

2. DETAILS OF THE NEW SHARES

The New Shares are issued free from all claims, pledges, mortgages, charges, liens and encumbrances and ranks in all respect *pari passu* with the then existing issued Shares at the time of the issue except that the New Shares will not rank for any dividends, rights, allotment or other distributions at the record date which falls on or before the date of issue of the New Shares.

The New Shares have been issued pursuant to the authority granted by Shareholders by way of an ordinary resolution at an annual general meeting of the Company held on 31 May 2017 ("**2017 AGM**") for the issue of Shares not exceeding 100% of the total number of issued Shares (excluding treasury shares) as at the date of the 2017 AGM, of which the aggregate number of shares to be issued other than on a pro-rata basis to the existing shareholders shall not exceed 50% of the total number of issued Shares (excluding treasury shares) (the "**Share Issue Mandate**").

As at the date of the Share Issue Mandate, the Company had an issued and paid up share capital of 1,310,858,710 Shares and as at the date of the ALA (as defined herein), 7,687,814 new Shares have been issued from the vesting of restricted share awards which was outstanding and/or subsisting as at the date of the Share Issue Mandate. Therefore, the total number of Shares that may be issued under the Share Issue Mandate as at the date of the ALA is 1,318,546,524 Shares, of which the maximum number of Shares to be issued other than on a pro-rata basis is 659,273,262 Shares.

The Company has also issued 291,004,980 Shares on 21 July 2017 pursuant to the July 15 and January 16 bond repayment and share issuance deeds dated 29 June 2017 entered into between the Company and certain bondholders, further details which can be found in the Company's announcement on SGXnet dated 29 June 2017 and 24 July 2017("**Bond Settlement Shares**").

As such, taking into consideration the issuance of the Bond Settlement Shares, the remaining number of new Shares that may be issued other than on a pro rata basis is 368,268,282. Accordingly, the allotment and issuance of new Shares underlying the Repayment Agreement of 22,290,322 New Shares falls within the limits of the Share Issue Mandate.

Including the issuance of the Bond Settlement Shares and the New Shares, the Company's issued and paid-up share capital will increase from 1,379,046,524 Shares ("**Existing Share Capital**") to 1,692,341,826 Shares ("**Enlarged Share Capital**"). The New Shares represents 1.62% of the Existing Share Capital and approximately 1.32% of the Enlarged Share Capital.

3. ADDITIONAL LISTING APPLICATION ("ALA")

The sponsor of the Company (the "**Sponsor**"), PrimePartners Corporate Finance Pte. Ltd., had made an application on behalf of the Company to the SGX-ST for the dealing in, listing of and quotation for the New Shares on Catalist of the SGX-ST ("**LQN**") and the LQN was received on 18 July 2017, and is subject to the compliance of the Company with the SGX-ST's listing requirements. The LQN is not to be taken as an indication of the merits of the Proposed Issue, New Shares, Repayment Agreement, the Company, its subsidiaries and their securities.

4. CONFIRMATION BY THE DIRECTORS

The Directors are of the opinion that after taking into consideration the Group's present bank and credit facilities (including the GEM Agreement), the working capital available to the Group is sufficient to meet its present requirements. Notwithstanding the aforementioned, the Company considers the repayment of the trade payables in the form of equity to be advantageous to the Group as it will, *inter alia*, ease the cash flow position of the Group and is in the long term interest of the Group.

5. INTERESTS OF DIRECTORS AND SUBSTANTIAL SHAREHOLDERS

None of the directors or substantial Shareholders of the Company has any interest, direct or indirect, in the issuance of the New Shares (other than through their shareholdings in the Company).

By Order of the Board
QT VASCULAR LTD.

Eitan Konstantino
Chief Executive Officer
24 July 2017

---

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. ("**Sponsor**") for compliance with the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement.*

This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made, or reports contained in this announcement.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).
